The head of the drug company behind EpiPens is speaking out about the firestorm created by the nearly 500 percent price hike of the device.
Mylan CEO Heather Bresch was called to testify before Congress last year about the huge price increase for the lifesaving allergy medicine to $600. After the controversy, the company cut the list price of generic EpiPens to $300.
In an interview with "CBS This Morning" co-host Norah O'Donnell, Bresch said more needs to be done to fix the health care system.
"What I realized, and what I went through this summer, EpiPen was a window into a broken system. And what I've conveyed, and I believe the discussion continues to validate, this isn't an EpiPen problem. This is a health care problem," said Bresch.
You can catch the rest of that interview including an exclusive look inside one of the company's lab Friday on CBS This Morning.
PO Box 4508